陳柏翰 Po CHEN, a seasoned international fintech professional who spent years at Morgan Stanley’s headquarters, made the bold decision to leave his high-paying job in a New York skyscraper and return to Taiwan. There, he embarked on an uncharted path in biotech entrepreneurship—driven by a deeply personal motivation: his beloved father’s battle with cancer.
The rise of AI is reshaping the way every industry operates and biotech and healthcare are no exception. 陳柏翰 Po CHEN understands well that the integration of information and the advancement of technology are critical for making precision medicine truly accessible and effective. That’s why he doesn’t just talk about ideals; he actively leads digital transformation efforts within the labs of CancerFree Biotech.
Today, CancerFree Biotech has fully digitized its lab records, replacing traditional paper-based documentation with real-time data entry and system management. While there was initial resistance to this shift, Chen knew it was an inevitable direction for the biotech industry.
But digitization is only the first step. The next priorities are automation and the integration of AI models. CancerFree Biotech is now working to combine data from cell-based drug response experiments with genetic testing and clinical information, using artificial intelligence for cross-analysis and prediction. The goal is to help physicians identify the most promising treatment options even under time constraints and with fragmented information.
陳柏翰 Po CHEN believes that the lab of the future should free humans from repetitive tasks and return their time to what truly matters: judgment, innovation, and being present for patients. “This isn’t a fantasy,” he says. “It’s a blueprint we’re actively working to realize.”
Look at the article:https://www.persona-media.com
